Durvalumab联合或不联合Tremelimumab联合化疗一线治疗转移性NSCLC

文章预览

SCI 28 September 2024 Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes from the Phase 3 POSEIDON Trial （J Thorac Oncol; IF:21.0） Peters S, Cho BC, Luft AV, Alatorre-Alexander J, Geater SL, Laktionov K, Trukhin D, Kim SW, Ursol GM, Hussein M et al: Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes from the Phase 3 POSEIDON Trial. J Thorac Oncol 2024. Corresponding author: Professor Solange Peters, MD, PhD, Centre Hospitalier Universitaire Vaudois, Lausanne University, Bugnon 46, Lausanne 1011, Switzerland. Email: solange.peters@chuv.ch Introduction: 介绍 The primary analysis (median follow-up 34.9 months across all arms) of the phase 3 POSEIDON study demonstrated a statistically significant overall survival (OS) improvement with first-line tremelimumab plus durvalumab and chemotherapy (T+D+CT) versus ………………………………